In this study, Huang et al. showed a reduction in the occurrence of severe AP, lower levels of inflammatory markers, and a decreased need for rescue analgesia with the COX-2 inhibitor regimen compared to standard of care in AP patients with predicted severe disease (based on an Acute Physiology and Chronic Health Evaluation II (APACHE II) score ≥ 8) [37]. The gene discussed is PTGS2; the disease is alkaline phosphatase measurement.